Prosecution Insights
Last updated: September 17, 2026
Application No. 18/749,420

SYNTHESIS OF PHOSPHATE DERIVATIVES

Non-Final OA §103
Filed
Jun 20, 2024
Priority
Jun 14, 2017 — GB 1709471.5 +3 more
Examiner
BERRY, LAYLA D
Art Unit
Tech Center
Assignee
Nucana PLC
OA Round
1 (Non-Final)
66%
Grant Probability
Favorable
1-2
OA Rounds
6m
Est. Remaining
75%
With Interview

Examiner Intelligence

Grants 66% — above average
66%
Career Allowance Rate
960 granted / 1455 resolved
+6.0% vs TC avg
Moderate +9% lift
Without
With
+9.0%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
53 currently pending
Career history
1481
Total Applications
across all art units

Statute-Specific Performance

§101
3.9%
-36.1% vs TC avg
§103
34.2%
-5.8% vs TC avg
§102
19.6%
-20.4% vs TC avg
§112
25.1%
-14.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1455 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . CONTINUING DATA This application is a CON of 17/888,312 08/15/2022 PAT 12054511 17/888,312 is a CON of 16/623,263 12/16/2019 PAT 11414452 16/623,263 is a 371 of PCT/GB2018/051638 06/14/2018 FOREIGN APPLICATIONS UNITED KINGDOM 1709471.5 06/14/2017 Claims 1-20 are pending. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1-12 are rejected under 35 U.S.C. 103 as being unpatentable over Griffith (WO 2016/083830 A1) in view of Yuan (CN106478753A, March 8, 2018). Yuan (US 2018/0244710 A1) is used as an English equivalent. Griffith teaches the synthesis of NUC-7738 from the phosphochloridate. See page 60. The reaction was done in anhydrous THF for 16 hours. Page 55. The compound is preferably the pure Rp or Sp diastereomer. Stereoisomers can be separated by conventional techniques such as preparative chromatography, enantiospecific synthesis or resolution, or resolved using a chiral HPLC column. Page 29. Preferably, free OH groups on the nucleoside are protected. Page 28. An exemplified protecting group was t-butyldimethylsilyl, which was removed in THF/water. Page 56. Another suitable solvent is isopropanol (paragraph bridging pages 27-28). Griffith does not teach synthesis of NUC-7738 from Formula IIb, which contains a phenolic leaving group instead of chloride leaving group. Yuan teaches that a prior art method for preparing NUC-1031 from the phosphochloridate results in a mixture of isomers. To solve this problem, Yuan prepared the following compound and separated the isomers by crystallization to use for preparation of a single diastereomer of NUC-1031. Pages 2-3. PNG media_image1.png 230 333 media_image1.png Greyscale Yuan teaches the reaction of 61502b with the -C(O)O-tBu group-protected nucleoside 61501c as shown on page 4. The reaction was done in THF with t-butylmagnesium chloride at room temperature until the reaction was complete. Finally, the protecting group was removed. PNG media_image2.png 389 419 media_image2.png Greyscale PNG media_image3.png 417 434 media_image3.png Greyscale See pages 4-9. It would have been obvious to one of ordinary skill in the art at the time the application was filed to modify Griffith’s method to use Yaun’s compound 61502 instead of the phosphochloridate. The skilled artisan would have used compound 61502 so that the isomers could be separated before reaction with the compound of claimed Formula IIIb. It would have been obvious to use a protected nucleoside to avoid side reactions, and Griffith and Yuan illustrate exemplary protecting groups for nucleosides. Griffith teaches removal of the protecting group in THF/water and teaches that isopropanol is an alternative suitable solvent. It would have been obvious to carry out deprotection in IPA/water instead of THF/water because Griffith teaches that IPA is a suitable solvent. The skilled artisan would have carried out the reaction until it was complete as taught by Yuan, using Griffith’s time of 16 hours as a guide. Claims 13-20 are not included in this rejection because neither Griffith nor Yuan teaches claimed step d). The prior art of record does not teach or suggest claimed step d). Conclusion Claims 1-12 are rejected. Claims 13-20 are objected to as depending from a rejected base claim. Any inquiry concerning this communication or earlier communications from the examiner should be directed to LAYLA D BERRY whose telephone number is (571)272-9572. The examiner can normally be reached 7:00-3:00 CST, M-F. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Scarlett Goon can be reached at 571-270-5241. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /LAYLA D BERRY/Primary Examiner, Art Unit 1693
Read full office action

Prosecution Timeline

Jun 20, 2024
Application Filed
Aug 21, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12735512
PREPARATION METHOD OF MILK OLIGOSACCHARIDES AND OLIGOSACCHARIDE POWDER AND FOOD PREPARED THEREBY
3y 6m to grant Granted Sep 15, 2026
Patent 12729248
THERMALLY MODIFIED STARCHES
3y 1m to grant Granted Sep 08, 2026
Patent 12714724
LOW ENDOTOXIN FUCAN COMPOSITIONS, SYSTEMS AND METHODS
2y 7m to grant Granted Aug 25, 2026
Patent 12708638
SEMICARBAZONE-BASED SAPONIN CONJUGATE
3y 5m to grant Granted Aug 18, 2026
Patent 12709648
PROCESS FOR MANUFACTURING OF NANOCRYSTALLINE CELLULOSE (NCC)
2y 8m to grant Granted Aug 18, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
66%
Grant Probability
75%
With Interview (+9.0%)
2y 9m (~6m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1455 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month